共 4 条
Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid
被引:2
|作者:
Massiot, Philippe
[1
]
Reygagne, Pascal
[2
]
Chagnoleau, Corinne
[1
]
Kanoun-Copy, Leila
[1
]
Pouradier, Florence
[1
]
Loussouarn, Genevieve
[1
]
Queille-Roussel, Catherine
[3
]
Jouni, Hussein
[4
]
Kerob, Delphine
[5
]
机构:
[1] LOreal Res & Innovat, St Ouen, France
[2] Hop St Louis, Ctr Sabouraud, 1 Ave Claude Vellefaux, F-75010 Paris, France
[3] Hop Archet Nice, CPCAD, Nice, France
[4] LOreal Res & Innovat, Aulnay Sous Bois, France
[5] Cosmet Act Int, Levallois Perret, France
关键词:
selenium disulfide;
scalp seborrheic dermatitis;
scalp;
corticosteroids;
QUALITY-OF-LIFE;
DANDRUFF;
BACTERIAL;
SKIN;
D O I:
10.1684/ejd.2023.4401
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Introduction: Seborrheic dermatitis (SD) is a chronic, relapsing, inflammatory disorder of the head and trunk. Objectives: To explore the potential of a 1% Selenium disulphide (SeS2)-based shampoo to prevent relapses of scalp SD (SSD) following corticosteroid/salicylic acid (TCS/SA) treatment. Materials & Methods: After a 2-week treatment with TCS/SA, adult patients with moderate-to-severe SSD received either the SeS2-based shampoo or its vehicle for eight weeks in a randomized, double-blinded fashion. Visits took place at baseline, weeks 2, 6 and 10. SSD severity was assessed based on erythema, flakes and pruritus; patients assessed the severity of pruritus. Global investigator and patient satisfaction were assessed at week 10. Results: Forty-eight adults were included. After four and eight weeks of post TCS/SA maintenance regimen, 8.1% and 16.7% in the SeS2, and 41.7% and 54.2% in the vehicle group relapsed, respectively. First median time-to-relapse in the vehicle group was 56 days; this was not reached for SeS2. After two weeks of TCS/SA, the prevalence of patients with no pruritus was 29.2% in the SeS2 group, and 41.7% in the vehicle group; it increased to 76.2% with SeS2 and to 57.1% with the vehicle at the end of the study. The clinical benefit of treatment with TCS/SCA was maintained in the SeS2 group only. Investigators and patients were highly satisfied with the efficacy of SeS2. Tolerance to SeS2 was excellent, with no reported adverse events. Conclusion: The SeS2-based shampoo significantly reduces the time-to-relapse of moderate-to-severe SSD flares. Its tolerance was excellent, with no reported adverse events.
引用
收藏
页码:13 / 18
页数:6
相关论文